Alphamab Oncology's Anbenitamab Regimen Cuts Progression or Death Risk 54% in Phase III Breast Cancer Trial

• Alphamab Oncology presented results from two Phase III trials of anbenitamab (KN026) at the 2026 European Society for Medical Oncology Congress.
• First-line anbenitamab with HB1801 delayed progression versus standard treatment in HER2-positive advanced breast cancer; China granted the application priority review.
• In previously treated HER2-positive gastric or gastroesophageal junction cancer, anbenitamab with chemotherapy prolonged survival versus chemotherapy alone.
• China cleared the gastric cancer regimen for marketing in May 2026 for patients previously treated with a trastuzumab-containing regimen.
• Severe adverse events were more frequent with anbenitamab regimens in both trials, though the breast cancer study identified no new safety signals.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alphamab Oncology published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261026-12382704), on October 26, 2026, and is solely responsible for the information contained therein.